Aller au contenu principal
2025 article

CLINICAL CHARACTERISTICS AND MANAGEMENT OUTCOMES OF SECONDARY TUMOR-ASSOCIATED NEOVASCULARIZATION IN RETINOBLASTOMA PATIENTS

0Citations signalées, ce qui n’est pas une note de qualité
3Institutions déclarées
1Pays d’affiliation déclarés

Rattachement africain : cn. Niveau de preuve : code pays fourni par la source.

Le résumé fourni par la source

PURPOSE: To describe the clinical characteristics of secondary tumor-associated neovascularization (STN) in retinoblastoma (RB) patients and the outcomes and complications of intravitreal injections of anti-vascular endothelial growth factor (anti-VEGF) in the treatment of STN. METHODS: A single-center retrospective study. Intravitreal injections of anti-VEGF were given to RB patients once STN was confirmed by fundus fluorescein angiography and performed monthly until neovascularization was resolved. Demographic characteristics, clinical characteristics, treatment outcomes, and complications after anti-VEGF therapy were recorded. RESULTS: STN was detected in 12 eyes of 11 RB patients with a mean age of onset of 15 months. Eleven eyes received intra-arterial chemotherapy (IAC) (mean: six cycles, range: 2-11 cycles) before neovascularization onset. After receiving a mean of 4.6 (range: 1-18) intravitreal anti-VEGF injections, six eyes first exhibited reduced neovascularization with no relapse; five eyes first achieved resolution of neovascularization, but recurrence was observed at follow-up; and one eye received two anti-VEGF injections, but control of neovascularization was not achieved and further injections were refused. Common complications related to anti-VEGF injection included tractional retinal detachment (n = 6) and hyaloid membranes (n =5). None of the eyes needed enucleation. All the patients were alive without extraocular extension or metastases (mean follow-up 64 months, range: 37-112 months). CONCLUSION: STN can occur in RB patients after multiple comprehensive therapies, especially IAC. Intravitreal anti-VEGF injection contributes to the resolution of neovascularization, but anti-VEGF treatment-related complications must be recognized and anticipated.

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.

Le contrôle bibliographique ouvert

DOI retrouvé dans Crossref DOI retrouvé ; titre concordant.

Titre Crossref
CLINICAL CHARACTERISTICS AND MANAGEMENT OUTCOMES OF SECONDARY TUMOR-ASSOCIATED NEOVASCULARIZATION IN RETINOBLASTOMA PATIENTS
Date Crossref
01/04/2026
Éditeur
Ovid Technologies (Wolters Kluwer Health)
Type
journal-article

Ce recoupement confirme des métadonnées liées au DOI. Il ne confirme ni la méthode ni les conclusions de l’étude, et il ne compte pas comme une seconde source scientifique indépendante.

Les institutions déclarées

Une affiliation ne permet pas de déduire la nationalité d’un auteur.

Les sujets associés

Ocular Oncology and TreatmentsRetinal Diseases and TreatmentsOcular Diseases and Behçet’s Syndrome

BNTIC News n’est pas le producteur de ces données. Les publications sont interrogées à la demande dans Crossref, OpenAIRE, DOAJ, Europe PMC, HAL, DataCite, AfricArXiv, ROR et la Banque mondiale, sans clé d’accès. OpenAlex reste optionnel. Aucun service payant n’est nécessaire et aucune donnée externe n’est enregistrée en base. Consulter les sources et leurs limites.